1996
Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial.
Ment L, Vohr B, Oh W, Scott D, Allan W, Westerveld M, Duncan C, Ehrenkranz R, Katz K, Schneider K, Makuch R. Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 1996, 98: 714-8. PMID: 8885951, DOI: 10.1542/peds.98.4.714.Peer-Reviewed Original ResearchMeSH KeywordsCerebral HemorrhageChi-Square DistributionChild DevelopmentChild, PreschoolCyclooxygenase InhibitorsHumansIndomethacinInfantInfant, NewbornInfant, PrematureInfant, Premature, DiseasesInfant, Very Low Birth WeightIntelligence TestsNeurologic ExaminationUltrasonography, Doppler, TranscranialConceptsLow-dose indomethacinMonths' corrected ageIntraventricular hemorrhageCorrected ageNeurodevelopmental followLong-term neurodevelopmental followLow birth weight infantsLow birth weight neonatesBirth weight infantsMean gestational ageBirth weight neonatesStandard neurologic examinationAdverse cognitive outcomesIncidence of deafnessDose indomethacinWeight infantsPreterm infantsProspective trialWeight neonatesCranial ultrasoundEarly administrationNeurodevelopmental outcomesNeurologic examinationCerebral palsyGestational age
1994
Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial.
Ment L, Ehrenkranz R, Duncan C, Scott D, Taylor K, Katz K, Schneider K, Makuch R, Oh W, Vohr B, Philip A, Allan W. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994, 93: 543-50. PMID: 8134206, DOI: 10.1542/peds.93.4.543.Peer-Reviewed Original ResearchConceptsLow birth weight neonatesSeverity of IVHBirth weight neonatesIntraventricular hemorrhageWeight neonatesDose indomethacinBirth weightGrade 4 intraventricular hemorrhageSerial cranial ultrasound examinationsSignificant adverse drug eventsPercent of neonatesPlacebo-controlled trialPatent ductus arteriosusCranial ultrasound examinationMajor risk factorAdverse drug eventsHours of ageFirst postnatal dayDuctal closureProphylactic indomethacinApgar scoreNeurodevelopmental handicapParenchymal involvementPlacebo groupAdverse events